



**HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Adempas - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: <input type="checkbox"/> Medicare	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:
Strength:
Directions / SIG:

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is Adempas being prescribed by or in consultation with a cardiologist or pulmonologist?

Yes

No

Q2. Is the patient 18 years of age or older?

Yes

No

Q3. Is the patient female and of reproductive potential?

Yes

No

Q4. Did the patient have a negative pregnancy test and enroll in the manufacturer's risk evaluation and mitigation strategy (REMS) program prior to initiating Adempas?

If yes, include confirmation of a negative pregnancy test prior to start of therapy and enrollment in the manufacturer's REMS program.

Yes

No

Q5. Does the patient have a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH)?

Yes

No

Q6. Has the diagnosis of pulmonary arterial hypertension (PAH) been confirmed by a complete right heart catheterization (RHC)? If yes, please attach RHC report.

PAH is defined as:

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS MEDICARE
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Adempas - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:

Prescriber Name:

- A) Mean pulmonary arterial pressure (mPAP) greater than 20 mmHg
B) A pulmonary capillary wedge pressure/ left ventricular end-diastolic pressure (PCWP/LVEDP) less than or equal to 15 mmHg
C) A pulmonary vascular resistance (PVR) greater than 3 Wood units
Yes No

Q7. Does the patient have a World Health Organization (WHO) functional class of II (Slight limitation of physical activity but comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope) OR III (Marked limitation of physical activity and comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope)?
Yes No

Q8. Does the patient have a diagnosis of World Health Organization (WHO) Group 4 pulmonary arterial hypertension (PAH)?
Yes No

Q9. Is there documentation confirming the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) and verifying the patient has recurrent or persisting pulmonary hypertension following pulmonary thromboendarterectomy or inoperable CTEPH?
Yes No

Q10. Will Adempas be used with nitrates, nitric oxide donors, or phosphodiesterase-5 inhibitors?
Yes No

Q11. Is there a treatment plan?
Yes No

Q12. Additional Information:

Q13. Requested Duration:
12 Months

Prescriber Signature

Date

2021 Medicare Prior Authorization Request